Lukeman D S, Fanestil D D
J Pharmacol Exp Ther. 1987 Jun;241(3):950-5.
The peripheral-type benzodiazepine receptor (PBR) has been autoradiographically localized to the thick ascending limb and early distal tubule. To elucidate further the role of this receptor in kidney function, we have examined the effects of all classes of diuretics on the binding of labeled PBR-specific ligands (R05-4864, PK 11195) to rat kidney membranes (13,000 X g X 10 min). Drugs capable of inhibiting R05-4864 binding by 50% at less than 200 microM included: metolazone (IC50 = 1 microM), indacrinone (IC50 = 42 microM), indapamide (IC50 = 58 microM), hydrochlorothiazide (HCTZ; IC50 = 117 microM) and trichloromethiazide (IC50 = 175 microM). Conversely, diuretics of the loop (e.g., furosemide), K+-sparing (e.g., triamterene), and carbonic anhydrase inhibitor (e.g., acetazolamide) classes exerted no significant effects on R05-4864 binding (IC50S greater than or equal to 1 mM). Inhibition by indacrinone was stereoselective. Thiazide-like compounds inhibited R05-4864 binding with a rank-order of potencies similar to that for their enhancement of in vivo natriuresis (metolazone greater than HCTZ approximately equal to trichlormethiazide greater than chlorothiazide). Scatchard analysis revealed that metolazone, indacrinone, indapamide and HCTZ inhibited R05-4864 binding by reducing Kd, with no effect on maximum binding. The apparent Kd of metolazone for the renal PBR was 3.8 X 10(-7) M. IC50 values of 14 metolazone derivatives for inhibition of R05-4864 binding correlated well (r = .71, P less than .01) with their natriuretic efficacies. PK 11195 binding to digitonin (1.2 mg/mg of protein)-solubilized membranes displayed the same rank-order of, but was twice as sensitive to inhibition by metolazone, indacrinone, indapamide and HCTZ.(ABSTRACT TRUNCATED AT 250 WORDS)
外周型苯二氮䓬受体(PBR)已通过放射自显影定位到髓袢升支粗段和远曲小管起始部。为进一步阐明该受体在肾功能中的作用,我们研究了各类利尿剂对标记的PBR特异性配体(R05 - 4864、PK 11195)与大鼠肾膜(13000×g×10分钟)结合的影响。在浓度低于200微摩尔时能抑制R05 - 4864结合50%的药物包括:美托拉宗(IC50 = 1微摩尔)、茚达立酮(IC50 = 42微摩尔)、吲达帕胺(IC50 = 58微摩尔)、氢氯噻嗪(HCTZ;IC50 = 117微摩尔)和三氯噻嗪(IC50 = 175微摩尔)。相反,袢利尿剂(如呋塞米)、保钾利尿剂(如氨苯蝶啶)和碳酸酐酶抑制剂(如乙酰唑胺)对R05 - 4864结合无显著影响(IC50≥1毫摩尔)。茚达立酮的抑制作用具有立体选择性。噻嗪类化合物抑制R05 - 4864结合的效力顺序与其增强体内利钠作用的顺序相似(美托拉宗>氢氯噻嗪≈三氯噻嗪>氯噻嗪)。Scatchard分析表明,美托拉宗、茚达立酮、吲达帕胺和氢氯噻嗪通过降低解离常数(Kd)来抑制R05 - 4864结合,而对最大结合量无影响。美托拉宗对肾PBR的表观Kd为3.8×10⁻⁷ M。14种美托拉宗衍生物抑制R05 - 4864结合的IC50值与其利钠效力相关性良好(r = 0.71,P<0.01)。PK 11195与洋地黄皂苷(1.2毫克/毫克蛋白质)增溶膜的结合显示出相同的效力顺序,但对美托拉宗、茚达立酮、吲达帕胺和氢氯噻嗪抑制作用的敏感性是前者的两倍。(摘要截短于250字)